Contract manufacturer: FDA has halted domestic pharma inspections
The FDA appears to have halted its domestic inspections of pharmaceutical facilities, although not before attempting to inspect a contract development and manufacturing organization (CDMO) on Monday and subsequently deciding to end the inspection early and announce the halt.
The CEO of the CDMO, who requested that he and his firm remain anonymous, explained to Focus via email how his company received a last-minute inspection request from an FDA inspector whose planned trip for inspections in Europe was canceled.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.